Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Curevac N.V. (NQ: CVAC )

9.095 -0.555 (-5.75%)
Streaming Delayed Price Updated: 12:34 PM EDT, Jun 1, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 217,412
Open 9.450
Bid (Size) 9.080 (4)
Ask (Size) 9.110 (2)
Prev. Close 9.650
Today's Range 8.851 - 9.560
52wk Range 5.630 - 19.67
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
CureVac Announces Financial Results for the First Quarter of 2023 and Provides Business Update
Via ACCESSWIRE
Why CohBar Shares Are Trading Lower By 161%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers 
Via Benzinga

Performance

YTD
+42.55%
+42.55%
1 Month
+29.93%
+29.93%
3 Month
+11.87%
+11.87%
6 Month
+25.45%
+25.45%
1 Year
-51.62%
-51.62%

More News

Read More
CureVac Announces Developments in Patent Litigation with Pfizer/BioNTech
Via ACCESSWIRE
Earnings Preview: CureVac
Via Benzinga
CureVac Announces Dosing of First Participant in Combined Phase 1/2 Study of Multivalent, Modified Influenza Vaccine Candidates Developed in Collaboration with GSK
Via ACCESSWIRE
CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2022 and Provides Business Update
Via ACCESSWIRE
CureVac to Report Fourth Quarter and Full-Year 2022 Financial Results and Business Updates on April 25, 2023
Via ACCESSWIRE
CureVac Announces Voting Results of Extraordinary General Meeting
Via ACCESSWIRE
Moderna Hypes 'Important Step' In Flu Shot Results, But Market Disagrees
Via Investor's Business Daily
Pfizer/BioNTech Get Ready For London Court Battle With Moderna Over COVID-19 Vaccine Patents
Via Benzinga
CureVac Announces Closing of $250 million Follow-on Public Offering of Common Shares
Via ACCESSWIRE
Why CureVac Shares Are Nosediving Today
Via Benzinga
Why Bed Bath & Beyond Fell Almost 30%; Here Are 20 Stocks Moving Premarket
Via Benzinga
CureVac Announces Proposed Public Offering of Common Shares
Via ACCESSWIRE
CureVac Welcomes Myriam Mendila as New Chief Development Officer
Via ACCESSWIRE
CureVac Named as One of the World’s Most Dynamic Innovators by LexisNexis(R)
Via ACCESSWIRE
CureVac Shares Pop After Encouraging Update From COVID-19, Flu mRNA Vaccine Programs
Via Benzinga
CureVac Announces Positive Data in Older Adults from COVID-19 and Flu mRNA Vaccine Development Programs
Via ACCESSWIRE
The 3 Best Biotech Stocks Under $1 to Buy for January
Via InvestorPlace
Why Jupiter Wellness Shares Are Trading Lower By Around 40%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
Concert Pharmaceuticals, Coeur Mining And Other Big Stocks Moving Higher On Thursday
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 19, 2023
Via Benzinga
Why Starbox Group Shares Are Trading Higher By 22%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Nasdaq, S&P 500 Futures Slump Ahead Of Netflix Earnings, Another Batch Of Economic Data
Via Benzinga
7 Biotech Stocks That Will Make You Rich in 10 Years
Via InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.